[Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Copyright policy )[Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoagulation with equal or better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific agent has been available for reversal of NOACs. Idarucizumab binds dabigatran for rapid reversal of its activity without procoagulant effects. Andexanet alpha (expected release in 2016) and PER977 are antidotes under clinical development. This article summarizes current and potential future options to antagonize NOACs.
Vitamin K, Antidotes, Administration, Oral, Anticoagulants, Humans, Hemorrhage, Prothrombin, Blood Proteins, Antibodies, Monoclonal, Humanized, Factor Xa Inhibitors
Vitamin K, Antidotes, Administration, Oral, Anticoagulants, Humans, Hemorrhage, Prothrombin, Blood Proteins, Antibodies, Monoclonal, Humanized, Factor Xa Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!